Parenteral Drugs (India) Limited (PDPL) Financial Statements
Parenteral Drugs (India) Limited Financial Overview
Parenteral Drugs (India) Limited's market cap is currently $101.08M. The company's EPS TTM is $-3.28; its P/E ratio is -0.11; and it has a dividend yield of 0.47%. Parenteral Drugs (India) Limited is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 84.96M | $ 121.53M | $ 240.25M | $ 319.98M | $ 2.17B |
| Gross Profit | $ 30.31M | $ 48.37M | $ 13.40M | $ 75.64M | $ 370.93M |
| Operating Income | $ -117.56K | $ -82.97K | $ -320.32K | $ -867.78K | $ -425.13M |
| EBITDA | $ 372.69M | $ -117.09M | $ -144.39M | $ -162.40M | $ -12.93M |
| Net Income | $ -763.62M | $ -1.22B | $ -1.14B | $ -1.48B | $ -1.19B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.00K | $ 569.89K | $ 1.08M | $ 953.02K | $ 764.25K |
| Total Assets | $ 4.84B | $ 5.68B | $ 5.52B | $ 5.41B | $ 8.90B |
| Total Debt | $ 1.07B | $ 10.72B | $ 9.46B | $ 8.40B | $ 8.25B |
| Net Debt | $ 1.07B | $ 10.72B | $ 9.46B | $ 8.40B | $ 8.24B |
| Total Liabilities | $ 13.08B | $ 12.51B | $ 11.13B | $ 9.87B | $ 10.27B |
| Stockholders' Equity | $ -8.24B | $ -6.83B | $ -5.61B | $ -4.47B | $ -1.36B |
| Cash Flow | |||||
| Free Cash Flow | $ -4.83M | $ 1.25B | $ 1.12B | $ 4.77B | $ 1.66B |
| Operating Cash Flow | $ -4.83M | $ 1.25B | $ 1.12B | $ 4.77B | $ 1.67B |
| Investing Cash Flow | $ 647.25M | $ 618.56K | $ 789.25K | $ 965.77M | $ -6.18M |
| Financing Cash Flow | $ -642.99M | $ -1.25B | $ -1.12B | $ -5.74B | $ -1.67B |
Currency in INR